About UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Clinical Trials at UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
During the past decade, UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro"
#1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator and "Seagen Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
According to Clinical.Site data, the most researched conditions in "UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro" are
"High-risk Non-muscle Invasive Bladder Cancer" (1 trials) and "Muscle Invasive Bladder Cancer" (1 trials). Many other conditions were trialed in "UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro" in a lesser frequency.
Clinical Trials Intervention Types at UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
Most popular intervention types in "UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro" are "Biological" (2 trials), "Drug" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Pembrolizumab" (2 trials), "BCG" (1 trials), "Cisplatin" (1 trials), "Enfortumab vedotin (EV)" (1 trials) and "Gemcitabine" (1 trials). Other intervention names were less common.
Clinical Trials Genders at UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
The vast majority of trials in "UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro" are
2 trials for "All" genders.
Clinical Trials Status at UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro
Currently, there are NaN active trials in "UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro".
undefined are not yet recruiting,
2 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".